🚨New “Gamma Trigger” Alert 📈

The market is breaking out. Make sure this stock is on your radar                                                                                                                                                                                                                                                                                                                                                                                                                 August 22, 2023 *Sponsored by Sica Media I am so fired up right now! After patiently waiting on the sidelines for the last week, I knew yesterday was the time to strike. I have been telling you in my recent live training sessions, and explaining what I was looking for in my emails. It was a pure and simple “Gamma Trigger” move for the market. You can clearly see it in the chart below that I zoomed in on. Now, here is what I am excited about right now… I am seeing the exact same setup happening right now with…  NLS Pharmaceutics AG (Nasdaq: NLSP) We don’t often see setups like these so it is imperative to take full advantage when they do come around. Make sure you pull up NLSP on your platform right now and start looking into it immediately, as the stock is already on the move today in pre-market. So what does NLS Pharmaceutics (NLSP) do? NLSP is a clinical-stage pharmaceutical company focusing on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. Worldwide, millions of people suffer from CNS disorders. [Over three million people]( across the globe are challenged by narcolepsy — an inability to regulate sleep-wake cycles. In the United States alone, [11 percent of children]( between four and eleven years old are distressed by a form of ADHD, creating a heavy burden on the individual, their families, and society as a whole. NLSP is seeking to address these markets and meet their needs. The proprietary drugs they’re releasing are poised to dominate the global narcolepsy drugs market that’s projected to reach over [$6.6 BILLION by 2030](! And just yesterday, the stock closed under a buck ($0.82 to be exact) – but what do analysts have to say? The analysts that cover it forecast NLSP to trade anywhere from $4 on the low side up to $6 on the higher side, as you can see on this chart from the [Wall Street Journal](… And, frankly, it’s not hard to see why. The company has a long track record of success that puts them [more than three times ahead]( of their nearest competitor… And their proprietary Mazidol treatment could be the key to their total domination of the sector. As it stands, Narcolepsy lacks what’s called a “monotherapy” — a one-step treatment, and most patients are treated with a cocktail of drugs that includes numerous Schedule I and II substances, including GHB (also known as the date rape drug). This leaves 94% of patients with the belief that a new, innovative, and safer means of treating narcolepsy is required. That’s where Mazidol comes in… It’s a drug with a 30-year history of commercial use in the U.S. and Europe as an appetite suppressant under the name “Sanorex,” and it’s been used in Europe for nearly 40 years as an off-label treatment. For those of you who don’t know, an “off-label” treatment is one that a doctor prescribes for a use that the drug isn’t necessarily intended for. But now, NLSP is taking Mazidol into prime time as they undergo Phase 2 clinical trials, a process which we’ve seen lead to massive momentum for biotech stocks (as we saw during the Pandemic). Like when AstraZeneca launched clinical trials for a COVID vaccine — Investors who jumped in before the trial went live were capable of snatching up a 55% gain — in just three months! They say history doesn’t always repeat itself, but it often rhymes… And since we’ve witnessed this same story play out like clockwork over the years… Receiving the trial authorization could be the start of a runup for NLSP. If all continues to go well, a series of successful drug trials is capable of sending this stock into overdrive. And the news couldn’t be better for NLSP lately. How many small companies do you see [announcing]( “Phase 3 Trials?” But it’s not just about the product, or the testing — it’s about the leadership behind this organization. [Its roster of heavy hitters]( is absolutely stunning, and gives me a huge boost of confidence in their potential to make waves in the sector. Leadership’s wide range of expertise has landed NLSP partnerships with some of the top narcolepsy research institutions in the world, including: - Université de Lausanne (UNIL) (preclinical projects) - University of Berne (narcolepsy research), Swiss Narcolepsy Network (narcolepsy research) - (BVF Partners L.P (financial partnership) - Narcolepsy Network - The Narcolepsy Foundation - The Sleep Consortium - Hypersomnia Foundation - Wake Up Narcolepsy But just because I (and all of these institutions) love this stock doesn’t mean you have to. It’s critical that you do your own research before deciding if NLSP is right for your portfolio, and a great place to start would be right here at [the company’s website.]( This is an urgent situation, so make sure you look into NLSP right away. To YOUR Success! P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of my latest HOT STOCK ideas! *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.  Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull  DISCLAIMER *PAID ADVERTISEMENT. Raging Bull has been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on August 22 through August 24, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NLS Pharmaceutics AG, increased trading volume, and possibly an increased share price of NLS Pharmaceutics AG’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NLS Pharmaceutics AG, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. Update your email preferences or unsubscribe [here]( © Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States